1. Home
  2. MDWD vs NKSH Comparison

MDWD vs NKSH Comparison

Compare MDWD & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • NKSH
  • Stock Information
  • Founded
  • MDWD 2000
  • NKSH 1891
  • Country
  • MDWD Israel
  • NKSH United States
  • Employees
  • MDWD N/A
  • NKSH N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • NKSH Major Banks
  • Sector
  • MDWD Health Care
  • NKSH Finance
  • Exchange
  • MDWD Nasdaq
  • NKSH Nasdaq
  • Market Cap
  • MDWD 184.8M
  • NKSH 180.8M
  • IPO Year
  • MDWD 2014
  • NKSH N/A
  • Fundamental
  • Price
  • MDWD $17.64
  • NKSH $29.14
  • Analyst Decision
  • MDWD Strong Buy
  • NKSH Strong Buy
  • Analyst Count
  • MDWD 1
  • NKSH 1
  • Target Price
  • MDWD $25.00
  • NKSH $38.00
  • AVG Volume (30 Days)
  • MDWD 68.1K
  • NKSH 14.2K
  • Earning Date
  • MDWD 11-26-2024
  • NKSH 10-24-2024
  • Dividend Yield
  • MDWD N/A
  • NKSH 5.18%
  • EPS Growth
  • MDWD N/A
  • NKSH N/A
  • EPS
  • MDWD N/A
  • NKSH 1.44
  • Revenue
  • MDWD $19,720,000.00
  • NKSH $43,450,000.00
  • Revenue This Year
  • MDWD $10.37
  • NKSH N/A
  • Revenue Next Year
  • MDWD $26.36
  • NKSH $19.72
  • P/E Ratio
  • MDWD N/A
  • NKSH $20.17
  • Revenue Growth
  • MDWD N/A
  • NKSH N/A
  • 52 Week Low
  • MDWD $11.04
  • NKSH $26.00
  • 52 Week High
  • MDWD $24.00
  • NKSH $35.00
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 49.76
  • NKSH 51.10
  • Support Level
  • MDWD $15.80
  • NKSH $26.00
  • Resistance Level
  • MDWD $19.60
  • NKSH $29.66
  • Average True Range (ATR)
  • MDWD 0.98
  • NKSH 0.94
  • MACD
  • MDWD 0.06
  • NKSH 0.18
  • Stochastic Oscillator
  • MDWD 48.42
  • NKSH 85.79

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

Share on Social Networks: